Cost of nitric oxide is exorbitantBMJ 2002; 325 doi: https://doi.org/10.1136/bmj.325.7359.336 (Published 10 August 2002) Cite this as: BMJ 2002;325:336
- C M Pierce, consultant paediatric intensivist.,
- M J Peters, consultant paediatric intensivist,
- G Cohen, senior lecturer in paediatric cardiothoracic surgery,
- A P Goldman, consultant paediatric intensivist.,
- A J Petros, consultant paediatric intensivist. (PETROA.CAR1.GOSH@cats.nhs.uk)
- Intensive Care Units, Great Ormond Street Hospital for Children NHS Trust, London WC1NH 3JH
EDITOR—Evidence based medicine is the gold standard for practice, and pharmaceutical companies appreciate the power of evidence based medicine. A positive result in a randomised controlled study produces pressure to use a specific agent regardless of cost.
High costs seem to predominate in intensive care. Over the past 10 years several expensive treatments have been launched and subsequently failed. Inhaled nitric oxide (iNO) was the reverse, being initially inexpensive, and is of proved efficacy in reducing morbidity.
Recently, two randomised controlled studies have shown improved oxygenation1 …